Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 9, 2003, Pages 392-396

  Mahmood, I ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bayesian estimation; Clearance; Sparse sampling

Indexed keywords

DRUG;

ACCURACY; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; NORMAL HUMAN; POPULATION RESEARCH; PREDICTION; TIME; VOLUNTEER;

EID: 0141738721     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41392     Document Type: Article

References (18)

1. Denaro CP, Jacob P, Benowitz NL 1998 Evaluation of pharmacokinetic methods used to estimate caffeine clearance and comparison with a Bayesian forecasting method. Ther Drug Monit 20: 78-87
2. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL 1988 An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 44: 232-238
3. Garraffo R, Iliadis A, Cano JP, Dellamonica P, Lapalus P 1989 Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin. J Pharm Sci 78: 753-757
4. Gaulier JM, Boulieu R, Fischer C, Mauguiere F 1997 Predictions of carbamazepine concentrations using a Bayesian program (PKS system, Abbott): a retrospective evaluation in an outpatient population. J Pharm Pharmacol 49: 734-736
5. Gentili D, Zucchetti M, Torri V, Sessa C, Jong J, Cavalli F, D'Incalci M 1993 A limited sampling model for the pharmacokinetics of etoposide orally. Cancer Chemother Pharmacol 32: 482-486
6. Ludden M 1988 Population pharmacokinetics. J Clin Pharmacol 28: 1059-1063
7. max: a computer simulation analysis. Int J Clin Pharmacol 37: 439-445
8. max). Biopharm Drug Dispos 18: 117-126
9. max of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product. Br J Clin Pharmacol 45: 241-246
10. max in toxicokinetics. J Pharm Sci 86: 579-583
11. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L 1988 Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48: 4127-4130
12. Ratain MJ, Vogelzang NJ 1987 Limited sampling models for vinblastine pharmacokinetics. Cancer Treat Rep 71: 935-939
13. Schumacher GE 1985 Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharmacol 4: 84-92
14. Sorensen BT, Stromgren A, Jackobson P, Jackobson A 1993 A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324-327
15. max) and area under the curve (AUC). Ther Drug Monit 19: 79-82
16. Tanigawara Y, Yano I, Kawakatsu K, Nishimura K, Yasuhara M, Hori R 1994 Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters and pharmacostatistical model. J Pharmacokinet Biopharm 22: 59-71
17. Vozeh S, Steimer C 1987 Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis. J Pharmacokinet Biopharm 15: 511-528
18. Williams PJ, Browne JL, Patel RA 1989 Bayesian forecasting of serum lithium concentrations. Comparison with traditional methods. Clin Pharmacokinet 17: 45-52